Bioengineering & Translational Medicine · 8 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This preclinical study tested human adipose-derived stem cells engineered to transiently secrete TGF-β3 and IL-10 via modified mRNA. In rat wound models and keloid cells, the combination therapy improved scar-free healing metrics like collagen organization and reduced myofibroblast activity.
This preclinical study investigated human adipose-derived stem cells (hADSCs) loaded with modified mRNA (modRNA) for transforming growth factor-β3 (TGF-β3) and interleukin-10 (IL-10). In a dorsal skin injury model in rats, hADSCs^dual^ (loaded with both modRNAs) improved collagen deposition, extracellular matrix organization, neovascularization, and skin appendage regeneration compared to controls. In vitro, this treatment inhibited proliferation and migration of keloid fibroblasts and reversed the myofibroblast phenotype. An ex vivo keloid explant model showed increased matrix metalloproteinase (MMP) expression and collagen degradation after treatment. The findings suggest a synergistic therapeutic platform for scar prevention, but safety and efficacy in humans require further validation.
